JP2022539038A5 - - Google Patents

Info

Publication number
JP2022539038A5
JP2022539038A5 JP2021576604A JP2021576604A JP2022539038A5 JP 2022539038 A5 JP2022539038 A5 JP 2022539038A5 JP 2021576604 A JP2021576604 A JP 2021576604A JP 2021576604 A JP2021576604 A JP 2021576604A JP 2022539038 A5 JP2022539038 A5 JP 2022539038A5
Authority
JP
Japan
Prior art keywords
cells
macrophages
bone marrow
marrow cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021576604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038115 external-priority patent/WO2020263650A1/en
Publication of JP2022539038A publication Critical patent/JP2022539038A/ja
Publication of JP2022539038A5 publication Critical patent/JP2022539038A5/ja
Pending legal-status Critical Current

Links

JP2021576604A 2019-06-27 2020-06-17 骨髄細胞炎症性表現型を調節するための抗ｌｒｒｃ２５組成物及び方法、ならびにその使用 Pending JP2022539038A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867593P 2019-06-27 2019-06-27
US62/867,593 2019-06-27
PCT/US2020/038115 WO2020263650A1 (en) 2019-06-27 2020-06-17 Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (2)

Publication Number Publication Date
JP2022539038A JP2022539038A (ja) 2022-09-07
JP2022539038A5 true JP2022539038A5 (https=) 2023-06-26

Family

ID=74060354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576604A Pending JP2022539038A (ja) 2019-06-27 2020-06-17 骨髄細胞炎症性表現型を調節するための抗ｌｒｒｃ２５組成物及び方法、ならびにその使用

Country Status (10)

Country Link
US (1) US20220363752A1 (https=)
EP (1) EP3990017A4 (https=)
JP (1) JP2022539038A (https=)
KR (1) KR20220042131A (https=)
CN (1) CN114423452A (https=)
AU (1) AU2020306772A1 (https=)
BR (1) BR112021026411A2 (https=)
CA (1) CA3142838A1 (https=)
IL (1) IL289166A (https=)
WO (1) WO2020263650A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120018859A (zh) * 2022-10-05 2025-05-16 尚华创新公司 抗尿激酶型纤溶酶原激活物受体抗体及其使用方法
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101122628B1 (ko) * 2009-02-16 2012-04-12 한국화학연구원 노닐페놀에 의해 유도된 생식독성 진단용 바이오마커 및 이를 이용한 생식독성 진단 방법
WO2014089124A1 (en) * 2012-12-03 2014-06-12 Cenexys, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
WO2016203053A2 (en) * 2015-06-18 2016-12-22 Thomas Mole Herd Methods of characterising cancer
WO2017004153A1 (en) * 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
WO2017068164A1 (en) * 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
CA3027452A1 (en) * 2016-06-14 2017-12-21 Advanced Biodesign Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis
WO2018014001A1 (en) * 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
EP3813881A4 (en) * 2018-06-29 2022-09-14 Verseau Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF MONOCYTE AND MACROPHAGE INFLAMMATION PHENOTYPES AND IMMUNOTHERAPY USES THEREOF

Similar Documents

Publication Publication Date Title
JP2021529753A5 (https=)
JP7564122B2 (ja) 光免疫療法のための方法および関連バイオマーカー
JP2023527410A5 (https=)
US20220169694A1 (en) Chimeric antigen receptor t cell therapy
CN112218888A (zh) 使用肿瘤微环境的特征的嵌合受体t细胞治疗
CN112703012A (zh) 治疗癌症的方法
JP2022535550A5 (https=)
JP2022535417A5 (https=)
EP4147053B1 (en) Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
EP3325967B1 (en) Methods for detecting tissue infiltrating nk cells
JP2022540768A5 (https=)
US20250313855A1 (en) Chimeric antigen receptor t cell therapy
JP2021500336A (ja) 抗ｃｄ４７及び抗ｐｄ−ｌ１による卵巣癌の処置
JP2022539038A5 (https=)
JP2023501487A (ja) 白血球上での細胞表面マーカーの発現を制御するための抗Ｃｌｅｖｅｒ－１剤、および抗Ｃｌｅｖｅｒ－１に基づくがん治療を導くためのこれらの使用
EP3388073A1 (en) Targeting mesothelin in brain cancer
EP4384276A1 (en) Biomarkers for cd40 agonist therapy
WO2022256562A2 (en) Methods of treating cancer with cd-40 agonists
US20240158869A1 (en) Factors for optimizing immunotherapy
AU2018210235A1 (en) Modulation of tumor cell susceptibility
Vos et al. Effect of pembrolizumab on biomarkers related to intratumoral immunity, proliferation and apoptosis in early breast cancer
WO2026096859A2 (en) Biomarkers related to immunotherapy efficacy
Kaewkangsadan Evaluation of immune cell infiltrates and expression of cytokines/biological molecules in the microenvironment of tumours and tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy: crucial contribution to immune-mediated tumour cell death
JP2026510915A (ja) 免疫療法の有効性に対する腫瘍微小環境の影響
HK40044133A (en) Chimeric receptor t cell treatment using characteristics of the tumor microenvironment